Podchaser Logo
Home
147 -  Crizotinib breakthrough therapy designation; certolizumab for moderate-to-severe plaque psoriasis; Zeto wireless EEG headset; larotrectinib in solid tumors; Raviten for intradialytic hypotension

147 - Crizotinib breakthrough therapy designation; certolizumab for moderate-to-severe plaque psoriasis; Zeto wireless EEG headset; larotrectinib in solid tumors; Raviten for intradialytic hypotension

Released Wednesday, 30th May 2018
Good episode? Give it some love!
147 -  Crizotinib breakthrough therapy designation; certolizumab for moderate-to-severe plaque psoriasis; Zeto wireless EEG headset; larotrectinib in solid tumors; Raviten for intradialytic hypotension

147 - Crizotinib breakthrough therapy designation; certolizumab for moderate-to-severe plaque psoriasis; Zeto wireless EEG headset; larotrectinib in solid tumors; Raviten for intradialytic hypotension

147 -  Crizotinib breakthrough therapy designation; certolizumab for moderate-to-severe plaque psoriasis; Zeto wireless EEG headset; larotrectinib in solid tumors; Raviten for intradialytic hypotension

147 - Crizotinib breakthrough therapy designation; certolizumab for moderate-to-severe plaque psoriasis; Zeto wireless EEG headset; larotrectinib in solid tumors; Raviten for intradialytic hypotension

Wednesday, 30th May 2018
Good episode? Give it some love!
Rate Episode

May 30, 2018

Please subscribe, rate and review if you like this podcast. Thank you! The podcast website is http://newfdaapprovals.com

1:01 Pfizer’s XALKORI® (crizotinib) receives FDA breakthrough therapy designation in two new indications https://investors.pfizer.com/investor-news/press-release-details/2018/Pfizers-XALKORI-crizotinib-Receives-FDA-Breakthrough-Therapy-Designation-in-Two-New-Indications/default.aspx

3:14 UCB announces the approval of CIMZIA® (certolizumab pegol) for moderate-to-severe plaque psoriasis https://www.prnewswire.com/news-releases/ucb-announces-the-approval-of-cimzia-certolizumab-pegol-for-moderate-to-severe-plaque-psoriasis-representing-an-important-new-option-for-patients-in-the-us-300655645.html

5:29 Zeto announces first dry electrode, wireless EEG headset approved by FDA for clinical use https://www.prnewswire.com/news-releases/zeto-announces-first-dry-electrode-wireless-eeg-headset-approved-by-fda-for-clinical-use-300655286.html

7:40 FDA accepts larotrectinib new drug application and grants priority review solid tumors harboring https://www.prnewswire.com/news-releases/fda-accepts-larotrectinib-new-drug-application-and-grants-priority-review-300655627.html

10:17 TrioxBio Announces Fast Track Designation Granted by U.S. FDA to Raviten® https://www.prnewswire.com/news-releases/trioxbio-announces-fast-track-designation-granted-by-us-fda-to-raviten-for-the-treatment-of-intradialytic-hypotension-683935721.html 

Please check out my weekly podcast AI in Medicine. In this week’s episode I talk to Chris Mansi who is CEO and co-founder of Viz.ai. Viz technology helps detect LVO and uses an AI algorithm to classify patients with stroke who need immediate treatment. Check it out at aimedicinenews.com

Music credit: freemusicarchive.org/music/MindsEye/Yellow_Taxi/

Show More
Rate

Join Podchaser to...

  • Rate podcasts and episodes
  • Follow podcasts and creators
  • Create podcast and episode lists
  • & much more

Episode Tags

Do you host or manage this podcast?
Claim and edit this page to your liking.
,

Unlock more with Podchaser Pro

  • Audience Insights
  • Contact Information
  • Demographics
  • Charts
  • Sponsor History
  • and More!
Pro Features